{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:27:53Z","timestamp":1762900073345,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clgc.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T15:38:59Z","timestamp":1616081939000},"page":"e248-e254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Apparent Diffusion Coefficient Value can Predict Poor Bacillus Calmette\u2013Gu\u00e9rin Responders in T1HG\/NMIBC: Prospective Cohort Study"],"prefix":"10.1016","volume":"19","author":[{"given":"Khaled M","family":"Abd Elwahab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esam A E","family":"Desky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed S","family":"Eldery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faten Fawzy","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed M","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-9185","authenticated-orcid":false,"given":"Islam M","family":"El-Babouly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2021.03.001_bib0001","first-page":"1","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat Rev Disease Primers"},{"key":"10.1016\/j.clgc.2021.03.001_bib0002","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0003","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer","volume":"71","author":"Witjes","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0004","series-title":"Bladder Cancer: Diagnosis and Clinical Management","first-page":"89","article-title":"HGT1 bladder cancer: diagnosis and treatment","author":"Gaya","year":"2015"},{"key":"10.1016\/j.clgc.2021.03.001_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2007.08.015","article-title":"Intravesical pharmacotherapy for non\u2013muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results","volume":"53","author":"Witjes","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0006","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","article-title":"A retrospective analysis of 153 patients treated with or without intravesical Bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival","volume":"169","author":"Shahin","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0007","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.urology.2006.09.019","article-title":"Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guerin immunotherapy","volume":"69","author":"Margel","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2021.03.001_bib0008","first-page":"462","article-title":"Muscle-invasive and metastatic bladder cancer","volume":"71","author":"Witjes","year":"2015","journal-title":"Eur Urol Guidel"},{"key":"10.1016\/j.clgc.2021.03.001_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2012.09.057","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers","volume":"63","author":"Kamat","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2015.01.032","article-title":"Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature","volume":"68","author":"Kluth","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0011","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bju.12343","article-title":"Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy","volume":"113","author":"Shariat","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2021.03.001_bib0012","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.urolonc.2016.05.012","article-title":"Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer","volume":"34","author":"Chedgy","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0013","unstructured":"Forshult SE. Magnetic resonance imaging\u2013MRI\u2013an overview: Fakulteten f\u00f6r teknik-och naturvetenskap; 2007."},{"key":"10.1016\/j.clgc.2021.03.001_bib0014","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1593\/neo.81328","article-title":"Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations","volume":"11","author":"Padhani","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.clgc.2021.03.001_bib0015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/mrm.1910190208","article-title":"Diffusion imaging using stimulated echoes","volume":"19","author":"Merboldt","year":"1991","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.clgc.2021.03.001_bib0016","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1102\/1470-7330.2006.0021","article-title":"Diffusion-weighted magnetic resonance imaging and its application to cancer","volume":"6","author":"Charles-Edwards","year":"2006","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.clgc.2021.03.001_bib0017","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2214\/AJR.12.10348","article-title":"Utility of quantitative MRI metrics for assessment of stage and grade of urothelial carcinoma of the bladder: preliminary results","volume":"201","author":"Rosenkrantz","year":"2013","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0018","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.25011\/cim.v38i4.24262","article-title":"Sensitivity and specificity of diffusion-weighted magnetic resonance imaging in diagnosis of bladder cancers","volume":"38","author":"Zhai","year":"2015","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.clgc.2021.03.001_bib0019","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jmri.24148","article-title":"Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer","volume":"39","author":"Kobayashi","year":"2014","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.clgc.2021.03.001_bib0020","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.acra.2013.02.012","article-title":"Clinical value of T2-weighted imaging combined with diffusion-weighted imaging in preoperative T staging of urinary bladder cancer: a large-scale, multiobserver prospective study on 3.0-T MRI","volume":"20","author":"Wu","year":"2013","journal-title":"Acad Radiol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0021","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1007\/s00330-011-2174-7","article-title":"Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness","volume":"21","author":"Kobayashi","year":"2011","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0022","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0023","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000453670","article-title":"ERBB2 expression as potential risk-stratification for early cystectomy in patients with pT1 bladder cancer and concomitant carcinoma in situ","volume":"98","author":"Breyer","year":"2017","journal-title":"Urol Int"},{"key":"10.1016\/j.clgc.2021.03.001_bib0024","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clgc.2021.03.001_bib0025","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106866","article-title":"Quantitative apparent diffusion coefficient measurements obtained by 3-Tesla MRI are correlated with biomarkers of bladder cancer proliferative activity","volume":"9","author":"Sevcenco","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2021.03.001_bib0027","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.juro.2010.08.083","article-title":"Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical Bacillus Calmette-Gu\u00e9rin plus interferon-\u03b1","volume":"185","author":"Rosevear","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0028","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.crad.2018.05.022","article-title":"Apparent diffusion coefficient values obtained by unenhanced MRI predicts disease-specific survival in bladder cancer","volume":"73","author":"Sevcenco","year":"2018","journal-title":"Clin Radiol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0029","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.ejrad.2012.06.009","article-title":"Can pretreatment ADC values predict recurrence of bladder cancer after transurethral resection?","volume":"81","author":"Funatsu","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5387\/fms.2017-05","article-title":"Apparent diffusion coefficient on magnetic resonance imaging (MRI) in bladder cancer: relations with recurrence\/progression risk","volume":"63","author":"Kikuchi","year":"2017","journal-title":"Fukushima J Med Sci"},{"key":"10.1016\/j.clgc.2021.03.001_bib0031","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0032","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","article-title":"Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3)","volume":"27","author":"Hautmann","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0033","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0090-4295(99)00481-1","article-title":"Gender differences in stage distribution of bladder cancer","volume":"55","author":"Mungan","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2021.03.001_bib0034","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2013.11.040","article-title":"Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients","volume":"66","author":"Kluth","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.001_bib0035","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ejso.2014.03.003","article-title":"Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort","volume":"41","author":"Soave","year":"2015","journal-title":"Eur J Surg Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:46Z","timestamp":1761564886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767321000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1558767321000641"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2021.03.001","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apparent Diffusion Coefficient Value can Predict Poor Bacillus Calmette\u2013Gu\u00e9rin Responders in T1HG\/NMIBC: Prospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}